190 related articles for article (PubMed ID: 4005834)
1. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole.
Grem JL; Fischer PH
Cancer Res; 1985 Jul; 45(7):2967-72. PubMed ID: 4005834
[TBL] [Abstract][Full Text] [Related]
2. Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels.
Grem JL; Fischer PH
Cancer Res; 1986 Dec; 46(12 Pt 1):6191-9. PubMed ID: 2946402
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.
Geoffroy FJ; Allegra CJ; Sinha B; Grem JL
Oncol Res; 1994; 6(12):581-91. PubMed ID: 7787251
[TBL] [Abstract][Full Text] [Related]
4. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
[TBL] [Abstract][Full Text] [Related]
5. 5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies.
Brunetti I; Falcone A; Calabresi P; Goulette FA; Darnowski JW
Cancer Res; 1990 Jul; 50(13):4026-31. PubMed ID: 2354452
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
Curtin NJ; Harris AL; Aherne GW
Cancer Res; 1991 May; 51(9):2346-52. PubMed ID: 2015598
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the sensitivity of human colon cancer cells to growth inhibition by acivicin achieved through inhibition of nucleic acid precursor salvage by dipyridamole.
Fischer PH; Pamukcu R; Bittner G; Willson JK
Cancer Res; 1984 Aug; 44(8):3355-9. PubMed ID: 6744269
[TBL] [Abstract][Full Text] [Related]
8. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
9. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.
Aschele C; Sobrero A; Faderan MA; Bertino JR
Cancer Res; 1992 Apr; 52(7):1855-64. PubMed ID: 1532346
[TBL] [Abstract][Full Text] [Related]
10. Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid.
Moran RG; Scanlon KL
Cancer Res; 1991 Sep; 51(17):4618-23. PubMed ID: 1831402
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole.
Van Mouwerik TJ; Pangallo CA; Willson JK; Fischer PH
Biochem Pharmacol; 1987 Mar; 36(6):809-14. PubMed ID: 3566784
[TBL] [Abstract][Full Text] [Related]
12. Enhancement by uridine of the anabolism of 5-fluorouracil in mouse T-lymphoma (S-49) cells.
Parker WB; Klubes P
Cancer Res; 1985 Sep; 45(9):4249-56. PubMed ID: 2411399
[TBL] [Abstract][Full Text] [Related]
13. Dipyridamole potentiates adriamycin cytotoxicity by a mechanism other than inhibiting nucleoside uptake.
Kusumoto H; Maehara Y; Anai H; Kumashiro R; Sugimachi K
Anticancer Res; 1991; 11(4):1539-42. PubMed ID: 1746911
[TBL] [Abstract][Full Text] [Related]
14. Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
Zhen YS; Taniki T; Weber G
Oncol Res; 1992; 4(2):73-8. PubMed ID: 1596584
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity.
Smith PG; Thomas HD; Barlow HC; Griffin RJ; Golding BT; Calvert AH; Newell DR; Curtin NJ
Clin Cancer Res; 2001 Jul; 7(7):2105-13. PubMed ID: 11448930
[TBL] [Abstract][Full Text] [Related]
16. Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8.
Benz C; Cadman E
Cancer Res; 1981 Mar; 41(3):994-9. PubMed ID: 7459888
[TBL] [Abstract][Full Text] [Related]
17. 5-Fluoropyrimidine-induced DNA damage in human colon adenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole.
Lönn U; Lönn S; Nylen U; Winblad G
Cancer Res; 1989 Mar; 49(5):1085-9. PubMed ID: 2521812
[TBL] [Abstract][Full Text] [Related]
18. Biochemical modulation of fluorouracil by dipyridamole: preclinical and clinical experience.
Grem JL
Semin Oncol; 1992 Apr; 19(2 Suppl 3):56-65. PubMed ID: 1557658
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of 5-fluorouracil cytotoxicity by combining hyperthermia and dipyridamole in vitro.
Maehara Y; Sakaguchi Y; Kusumoto T; Kusumoto H; Sugimachi K
Anticancer Res; 1989; 9(4):967-9. PubMed ID: 2817823
[TBL] [Abstract][Full Text] [Related]
20. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs.
Cole PD; Smith AK; Kamen BA
Cancer Chemother Pharmacol; 2002 Aug; 50(2):111-6. PubMed ID: 12172974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
